Join us in the latest episode of the Drug Science Podcast, where we talk with Dr. Grace Blest-Hopley, Director of Research for Heroic Hearts Project UK, Chief Scientific Officer of NW PharmaTech, and founder and CEO of Hystelica. In the episode, she explore where psychedelic studies have largely ignored women’s physiology, particularly in failing to acknowledge and control for hormonal fluctuations. Grace particularly emphasises the necessity for greater investigations and understandings around the intersection of psychedelics and the menstrual cycle, explaining how Hystelica attempts to bridge this gap with naturalistic and observational studies. Throughout, the discussion examines how, by researching these unknowns, we can discover new treatment opportunities that better serve women’s health.

Heroic Hearts Project UK

Hystelica

NWPharmaTech

MDMA

Psilocybin Retreats Study

Mothers of the mushroom

Microdosing Study

In this latest episode of the Drug Science Podcast, we talk with Natalia Rebollo and Jesús Alonso Olamendi of the International Center for Ethnobotanical Education, Research, and Service (ICEERS). They discuss the lasting legacy of colonialism in the psychedelic culture of indigenous communities, stressing the need for the sacredness of these substances to be uplifted and not commodified. Throughout, they explore their work with ICEER’s Ayahuasca Defense Fund and how it has begun to change the narrative surrounding psychedelics in prohibitionist countries. Operating between indigenous communities and the Western world, they provide a unique perspective that shows how both communities can learn from each other.

ICEERS

Ayahuasca Defense Fund

Ayahuasca

DMT

Ayahuasca Legal Battle in France

Technical Report on Ayahuasca

Colombia's CND68 Resolution

Ibogaine

Spanish Ibogaine Trial

Contact Email

Tune in to the latest episode of the drug science podcast where David Nutt meets with Tim Kerr, a doctoral research student in Psychiatry at King’s College London. Tim discusses his journey from slowly falling into drug addiction and dealing whilst studying for his medical degree eventually leading to arrest and imprisonment. Tim shares how he used this time in an open prison to apply for and study a Neuroscience masters with Kings College London with the support of the Longford trust, a charity that supports people with lived experience of prison to access higher education.

 
 The Longford Trust

Howard League for Penal Reform

NHS Practitioner Health

Alcoholic liver disease

Jaundice

Ecstasy

Ketamine

Cocaine

Freud and cocaine

Nitrous oxide

GHB 

Spice

Weed

Venlafaxine

Modafinil 

Open and closed Prison

Alcoholics Anonymous

Join us in the latest episode of the Drug Science Podcast where David Nutt meets with Psychedelic psychotherapy experts Laurie Higbed and Owain Winfield to dive into how to use psychedelics in psychotherapy. In this episode, they discuss the different techniques used with different psychedelics for different conditions to optimise this type of therapy and why these differences are necessary. They discuss MDMA, Ketamine and Psilocybin in a range of applications including trauma and addictions.

MDMA

Ketamine

Psilocybin

Substance Misuse

PTSD

MAPS

MDMA study into Substance Use Disorder

Compass Pathways

Compass Pathways Psilocybin for Treatment Resistant Depression

Awakn life sciences

Amygdala

Link in show notes

In this episode, we meet with Bessel van Der kolk, a trauma based psychiatrist, author, researcher and educator. Since the 1970s his research has been in the area of post-traumatic stress and he is the author of four books including best seller “the body keeps score”. Within this episode, he dives into what trauma is and different research into the impact trauma can have on the body and brain. He further discusses various traditional and alternative treatments for trauma and where these may be appropriate for different people with specific emphasis on EMDR and MDMA.

The body keeps score 

Nutt's paper lancet psychiatry 50 years of failure 

MDMA 

SSRI

EMDR 

Gaba

Benzodiazepines

Rorschach test

Norepinephrine 

Bowlby 

MAPS

When the spirit catches you, you fall down

Neuroplasticity 

In this episode of the Drug Science Podcast, David Nutt meets with psychopharmacologist Phil Cowen and Psychiatrist Sameer Jauhar  to discuss the neuroscience behind and treatments for depression. Within the episode they touch on various neurotransmitters involved in depression as well as research studies into each of their impact, stigma around antidepressants and the role of psychedelics in treatment.

Depression

Serotonin

Tryptophan

Hamilton depression scale

Antidepressants

Geddes paper on preventing relapse

Support the Podcast

In this episode of the Drug Science podcast, we speak with Josh Dugdale of the Wasing Estate, described as a "mindful aristocrat." He shares his experiences with Ayahuasca in the Amazon and how they influenced his journey upon returning to the UK. Josh discusses the creation of a mindful and spiritual festival during the pandemic, its evolution over time, and its wider impact. He also explores the challenges surrounding psilocybin access rights, the changes needed in this area, and what the future of psychedelic reform might look like.

Medicine Festival 

Psilocybin Access Rights

Ayahuasca

Psilocybin

MDMA

Drug Science Reschedule Psilocybin

Medical Cannabis

PTSD Veterans 

PTSD

Industrial Hemp Licensing

DEFRA

Subscribe to podcast

Prof Ravi Das is a leading expert in psychopharmacology and cognitive neuroscience, with a career dedicated to understanding and developing innovative treatments for addiction and anxiety disorders. He completed his BSc in Psychology and MSc in Cognitive Neuroscience at University College London (UCL), followed by a PhD in Psychopharmacology at the UCL Clinical Psychopharmacology Unit.

Prof Das’s research takes a translational and experimental medicine approach, focusing on the mechanisms of memory plasticity and their role in the development of addictive and anxiety disorders. A key area of his work is memory reconsolidation—the process by which established memories become temporarily unstable when retrieved, creating an opportunity to modify maladaptive memories. By targeting these unstable memories, Prof Das explores how drug or behavioral interventions could potentially disrupt the cravings and relapse associated with addiction, the fear underlying anxiety disorders, or the flashbacks experienced in PTSD.

In addition to his work on memory reconsolidation, Prof Das is deeply interested in the phenomenology and effects of illicit drug use, as well as the role of cognitive and mindfulness-based strategies in treating substance use disorders. His research bridges the gap between scientific discovery and clinical application, with the ultimate goal of developing more effective, evidence-based treatments for mental health challenges.

Prof Celia Morgan

Prof Val Curran

Prof Sunjeev Kamboj

Memory Research and consolidation 

Biggest DMT study

Placebos in psychedelic clinical trials 

Prof Mitul Mehta

Psychedelic gold rush 

RFK Jr pro-psychedelics 

FDA reject Lykos decision 

UNITy screening form 

Wellcome Leap

LSD study 

Preparation for Psilocybin study

UNITy

Tune in to the latest episode of the drug science podcast where we meet with Dr James Morgan, Prof Chris Chandler and Prof Jo Neill, the founders of Street Drugs Discussions (SDD). They discuss the process which led to them founding SDD, a series of webinars featuring experts on drug policy and drugs featuring topics surrounding overdose prevention centres, trafficking, specific substances and more. They reflect on the journey which got them to their current position as well as future hopes for SDD. Further, in this episode, the speakers discuss specific research conducted into long term heroin use and learning theory of addiction. 

 
Street Drugs Discussions
Buvidal 

Wedinos

Barod

psycare

Diamorphine assisted treatment

Leap

Neil Woods Episode

Needle exchange

Trainspotting

Heroin

Crack cocaine

Nicotine

Alcohol 

MDMA

morphine

Drug Science Community Member

A conversation between Prof David Nutt and research scientist Dr Matthew X. Lowe.

Dr Matthew X. Lowe PhD is Director of Research for Realm of Caring and Executive Director for Unlimited Sciences, a not-for-profit, observational research organisation with a focus on cannabis and psychedelic use by underrepresented population groups and a toll-free info line providing evidence-based support for anyone using psychedelics.

In this episode, they discuss the vital role of observational and longitudinal research when it comes to the medicalisation of cannabis and psychedelics — and the importance for safetyof bringing real-world data into our collective knowledge base.

They start with the genesis of Realm of Caring and Unlimited Sciences. Both organisations were conceived following first-hand experience of the banned compounds they research being profoundly medically transformative — inspiring co-founder Heather Jackson to grow related research and make it freely available to all who stand to benefit from such education. The origin stories of the organisations are followed by Dr Lowe’s personal route to his current research role and the roots of his passion for pursuing psychedelic research questions.

Their focus then shifts to the present day with a comparison of roadblocks and red tape around researching cannabis and psychedelics in the UK and the US, noting the pioneering role that parents so often play in advocating for research into medicinal cannabis. Next comes a deeper exploration of specific properties of psychedelics that relate to their potential therapeutic applications, including their anti-addictive nature and positive habit-forming potential resulting from the neuroplastic window they potentiate — Unlimited Sciences has conducted the world’s largest naturalistic study on psilocybin use with further papers coming out on these implications.

For the remainder of the episode, Prof David Nutt and Dr Matthew Lowe go into specifics on several key projects from Realm of Caring and Unlimited Sciences, including:

-       The Realm of Caring Observational Research Registry, being done in collaboration with Johns Hopkins Cannabis Science Laboratory. This ongoing research is an IRB-approved online survey study looking at the effects on a variety of health conditions, in people who do and do not use cannabis. It is open to everyone in the world with internet access.
 
 

-       The Cannabis and Health Research Initiative (CHRI), another collaboration between Johns Hopkins and Realm of Caring, examining the patient-level impact of therapeutic cannabis use, through data collection and dissemination — aiming to aid clinical decision making and policymaking. 

And finally, two ceremonial research projects looking at ayahuasca, foregrounding the role of community and context in ceremonial psychedelic experiences — both exemplifying Unlimited Sciences’ diversification of the evidence base on psychedelics by collecting real world data on underrepresented population groups: 

-       With subjects who were Arabic-speaking women, a study exploring the psychological benefits of ayahuasca for refugees — with DrugScience collaborator Dr Robin Carhart-Harris. 
 

-       And, currently in data analysis, with first results set to release in 2025, an IRB-approved study about ayahuasca use in the LGBTQIA+ community in collaboration with Costa Rica plant medicine retreat Jungle Gayborhood, with an emphasis on the importance of set and setting being truly safe spaces in the sense of meeting the specific needs of participants involved. 

Find out more about Dr Matthew X. Lowe and Unlimited Sciences below! 

Dr Matthew X. Lowe 

Realm of Caring

Unlimited Sciences 

The Psychedelic Info Line

Charlotte’s Web, Charlotte Figi and Realm of Caring

Realm of Caring’s research library

Long-term CBD study (Realm of Caring)

Observational Research Registry (Realm of Caring)

World’s largest naturalistic study on psilocybin use (Unlimited Sciences)

Psychological benefits of ayahuasca for refugees (Unlimited Sciences)

Jungle Gayborhood

The LGBTQIA+ study